AirAvant Medical is a research-oriented, privately held company that focuses on developing and marketing innovative respiratory medical devices to treat obstructive sleep apnea and other breathing disorders. AirAvant has recently launched the Bongo® Rx, a groundbreaking EPAP device that is FDA-cleared to treat mild to moderate obstructive sleep apnea.

Holding numerous patents with several patents pending, AirAvant Medical continues to innovate revolutionary respiratory technologies for the sleep-disorder breathing market, which includes Obstructive Sleep Apnea, snoring, and COPD applications.

History

AirAvant Medical was founded by Bruce Sher, Shara Hernandez, Javier Collazo, and Ron Richard. The company’s founders were former executives at InnoMed Technologies, Inc., where they had developed and launched a highly acclaimed line of respiratory and sleep devices, including the Nasal-Aire, the Hybrid, and the Aloha CPAP interfaces. In 2019, AirAvant Medical introduced its flagship product – the Bongo® Rx.

Mission Statement

AirAvant Medical’s mission is to improve health and welfare by creating user-centered, non-surgical medical devices that treat respiratory disorders while minimizing impact to the patient’s lifestyle.

The Future

With the Bongo Rx, AirAvant Medical aims to transform the sleep apnea market by meeting the need for a more discreet and less encumbering solution than other therapies commonly prescribed today. AirAvant is working to ensure that patients in the U.S. and Canada can easily purchase the Bongo Rx, and plans on expanding availability to other countries.

Our company will continue developing cutting-edge respiratory medical devices to meet the demand for user-friendly design and effective treatment in the sleep-disorder breathing market. AirAvant Medical is committed to delivering innovative products, high product quality, and excellent customer service.

Meet The Founders

Shara Hernandez

Shara Hernandez

Co-Founder | Co-President

Bruce Sher

Bruce Sher

Co-Founder | Co-President

Javier Collazo

Javier Collazo

Co-Founder | Vice-President | General Manager

Ron Richard

Ron Richard

Co-Founder

Meet The Medical Technology Advisory Committee

Jerrold Kram, MD, FAASM

Medical Director at California Center for Sleep Disorders

Alameda, CA

Alan Lankford, PhD, FAASM

Sleep Medicine Clinician/Scientist, Director of Research at The Neurological Center of North Georgia and Chief Science Officer at SleepSafe Drivers

Gainesville, GA

Rafael Pelayo, MD, FAASM

Clinical Professor, Sleep Medicine Division at Stanford University School of Medicine and 2020 President-elect at California Sleep Society

Stanford, CA

Lynn M. Schmidt, PhD, RN, CNE

Dean, Nursing & Kinesiology at Anderson University

Anderson, IN

Why The Bongo® Rx Was Developed

A Treatment for Obstructive Sleep Apnea
Obstructive Sleep Apnea (OSA) affects approximately 30 million people in the U.S. alone. Some studies suggest that approximately 50% of patients stop using their CPAP machine, the predominant treatment for OSA, citing noise, discomfort, claustrophobia, inconvenience, and cost.

AirAvant Medical conceived the Bongo Rx as a discreet and user-friendly EPAP device to treat sleep apnea. AirAvant Medical (a DBA of InnoMed Healthscience) is registered with the U.S. Food and Drug Administration and its Bongo Rx has received FDA 510(k) Clearance for the treatment of mild to moderate obstructive sleep apnea (OSA).

An Alternative to CPAP Therapy
In most OSA cases today, CPAP treatment is prescribed by health professionals, and patients have very few other options. CPAP is a proven effective treatment for patients who can tolerate it; however, it involves a significant lifestyle adjustment.

Patients must cope with a strenuous breathing experience, bedside nuisance of the electronic equipment, obtrusive hoses, and bulky masks. Many patients ultimately find that they cannot adapt to CPAP and subsequently give up on treatment.

AirAvant believes that its Bongo Rx EPAP device provides patients and providers with a viable non-surgical alternative to CPAP, for cases where either (a) CPAP is not an effective option due to non-compliance or (b) the patient is seeking a treatment that is more convenient and less obtrusive than CPAP.

A Game-Changing Respiratory Medical Device
AirAvant Medical’s Bongo Rx device was nominated for a 2020 Edison Award. The Edison Awards historically recognize “game-changing” new products that embody human-centered design and innovation.

If you have any questions about the Bongo Rx or AirAvant Medical, or how you can become an authorized dealer of Bongo Rx, please complete the following form and we will get back to you directly. We look forward to working with you.

airavant medical logo

AirAvant Medical is a DBA of InnoMed Healthscience, Inc.